索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]夏平,杨浩.心力衰竭合并心房颤动:从基础科学到临床实践[J].国际心血管病杂志,2016,02:87-89.
点击复制

心力衰竭合并心房颤动:从基础科学到临床实践(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年02期
页码:
87-89
栏目:
综述
出版日期:
2016-03-20

文章信息/Info

Title:
-
作者:
夏平; 杨浩
241000 芜湖,皖南医学院附属弋矶山医院心血管内科
Author(s):
-
关键词:
心力衰竭; 心房颤动; 成纤维细胞成长因子-23; 心外膜脂肪
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.02.007
文献标识码:
-
摘要:
心力衰竭和心房颤动常因共同的危险因素和病理生理机制而共存,预后不佳。该文主要介绍心力衰竭合并心房颤动的病理生理机制、预后以及治疗策略。
Abstract:
-

参考文献/References

[1] 陈 鑫.心力衰竭与心房颤动[J].国际心血管病杂志,2010,37(4):216-218.
[2] Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure[J]. Eur J Heart Fail,2009,11(7): 676-683.
[3] 肖兴平,薛竟宜,李为民.心力衰竭合并心房颤动与心房纤维化研究[J].国际心血管病杂志,2012,39(2):68-70.
[4] Cha YM, Redfield MM, Shen WK, et al. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle[J]. Circulation,2004,109(23): 2839-2843.
[5] Tsai CT, Lai LP, Kuo KT, et al. Angiotensin Ⅱ activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling[J]. Circulation. 2008. 117(3): 344-355.
[6] Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling[J]. Cardiovasc Res,2004, 63(3): 423-432.
[7] Liao CH, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts[J]. J Clin Invest,2010,120(1): 242-253.
[8] Qu YC, Du YM, Wu SL, et al. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation[J]. Scand Cardiovasc J,2009,43(5): 292-297.
[9] Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation[J]. Cardiovasc Res,2002,54(2): 247-258.
[10] 宋 颖,胡耀豪,肖瑞平.β肾上腺素受体与心力衰竭[J].生命科学,2015,27(3):249-261.
[11] van der Velden HM, Ausma J, Rook MB, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat[J]. Cardiovasc Res,2000,46(3): 476-486.
[12] Savelieva I, John CA. Atrial fibrillation and heart failure: natural history and pharmacological treatment[J]. Europace,2004,5 Suppl 1: S5-S19.
[13] Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation[J]. Circulation,2014,129(2): 145-156.
[14] Mathew JS, Sachs MC, Katz R, et al. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis(MESA)and the Cardiovascular Health Study(CHS)[J]. Circulation,2014,130(4): 298-307.
[15] Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease[J]. Circulation,2009,119(19): 2545-2552.
[16] Gupta DK, Shah AM, Giugliano RP, et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48[J]. Eur Heart J,2014,35(22): 1457-1465.
[17] Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation[J]. Stroke,2008,39(6): 1901-1910.
[18] Jenny-Avital ER. Obesity and the risk of heart failure[J]. N Engl J Med,2002,347(23): 1887-1889.
[19] Lin YK, Chen YJ, Chen SA. Potential atrial arrhythmogenicity of adipocytes: implications for the genesis of atrial fibrillation[J]. Med Hypotheses,2010,74(6): 1026-1029.
[20] Lin YK, Chen YC, Chang SL, et al. Heart failure epicardial fat increases atrial arrhythmogenesis[J]. Int J Cardiol,2013,167(5): 1979-1983.
[21] Girerd N, Scridon A, Bessiere F, et al. Periatrial epicardial fat is associated with markers of endothelial dysfunction in patients with atrial fibrillation[J]. PLoS One,2013,8(10): e77167.
[22] Khan RS, Kato TS, Chokshi A, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation[J]. Circ Heart Fail,2012,5(3): 340-348.
[23] Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss[J]. J Am Coll Cardiol,2009,53(21): 1925-1932.
[24] Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management(AFFIRM)Study[J]. Circulation,2004,109(12): 1509-1513.
[25] Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure[J]. N Engl J Med,2008,358(25): 2667-2677.
[26] Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion(RACE)Study[J]. J Am Coll Cardiol,2004,43(2): 241-247.
[27] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J]. Eur Heart J,2010,31(19): 2369-2429.
[28] Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC). Developed in collaboration with the European Heart Rhythm Association(EHRA)[J]. Europace,2013,15(8): 1070-1118.

备注/Memo

备注/Memo:
通信作者:杨 浩,Email:yijishanyanghao@163.com
更新日期/Last Update: 2016-03-20